Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Mar 16, 2021

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

Mar 15, 2021

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

Mar 12, 2021

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Mar 11, 2021

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Mar 09, 2021

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

Mar 03, 2021

Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Jan 13, 2021

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Jan 05, 2021

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

Nov 09, 2020

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results

Nov 02, 2020

Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 41 - 50 of 93

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2023 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy